Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Vistusertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-D
- 18 Sep 2018 Status changed from recruiting to discontinued.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 Planned initiation date changed from 1 Apr 2017 to 1 Aug 2017.